H. Lundbeck A/S
Denmark · DK0061804697 · reports in DKK · Europe
The answers
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Is it growing?Good
- Revenue +12% in the year to Dec 31, 2025, on the year before.
- Is it a good business?Fair
- It earned 13% on its shareholders' equity in the year to Dec 31, 2025.
- Is it safe?Fair
- Equity is 48% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in DKK.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | DKK 18.2B | DKK 19.9B | DKK 22.0B | DKK 24.6B |
| Operating profit | DKK 2.9B | DKK 3.2B | DKK 3.3B | DKK 5.3B |
| Earnings per share | DKK 1.93 | DKK 2.31 | DKK 3.17 | DKK 3.22 |
| Cash from operations | DKK 3.5B | DKK 4.1B | DKK 3.3B | DKK 5.5B |
| Capital spending | DKK 371M | DKK 277M | DKK 508M | DKK 554M |
| Cash | DKK 3.5B | DKK 5.0B | DKK 4.7B | DKK 3.4B |
| Total assets | DKK 37.5B | DKK 37.4B | DKK 57.7B | DKK 52.1B |
| Equity | DKK 20.8B | DKK 22.0B | DKK 25.0B | DKK 24.9B |
What they do
In the company's own words, from the annual report.
The Group is engaged in research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders, which constitutes the Group’s single business (operating) segment
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.